Viking Therapeutics, Inc. (NASDAQ:VKTX – Get Free Report) CFO Greg Zante sold 66,756 shares of the stock in a transaction dated Friday, May 3rd. The shares were sold at an average price of $74.69, for a total value of $4,986,005.64. Following the completion of the sale, the chief financial officer now owns 174,854 shares of the company’s stock, valued at approximately $13,059,845.26. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.
Viking Therapeutics Price Performance
Shares of VKTX stock opened at $76.97 on Monday. The firm has a market capitalization of $8.49 billion, a price-to-earnings ratio of -82.76 and a beta of 1.12. Viking Therapeutics, Inc. has a 12-month low of $8.28 and a 12-month high of $99.41. The business has a 50 day simple moving average of $73.19 and a 200 day simple moving average of $37.89.
Viking Therapeutics (NASDAQ:VKTX – Get Free Report) last released its earnings results on Wednesday, April 24th. The biotechnology company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.27) by $0.01. During the same quarter last year, the firm posted ($0.25) EPS. On average, equities analysts anticipate that Viking Therapeutics, Inc. will post -1.08 EPS for the current fiscal year.
Institutional Investors Weigh In On Viking Therapeutics
Analysts Set New Price Targets
VKTX has been the subject of several recent research reports. Stifel Nicolaus reaffirmed a “buy” rating and issued a $80.00 price objective on shares of Viking Therapeutics in a research report on Friday, March 15th. Maxim Group reaffirmed a “buy” rating and set a $120.00 price target on shares of Viking Therapeutics in a report on Friday, March 15th. Oppenheimer boosted their price objective on shares of Viking Therapeutics from $116.00 to $138.00 and gave the stock an “outperform” rating in a report on Tuesday, March 26th. StockNews.com upgraded Viking Therapeutics to a “sell” rating in a research note on Thursday, April 25th. Finally, Raymond James boosted their price target on Viking Therapeutics from $37.00 to $115.00 and gave the stock an “outperform” rating in a research note on Tuesday, February 27th. One research analyst has rated the stock with a sell rating and ten have issued a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $112.25.
Check Out Our Latest Report on Viking Therapeutics
Viking Therapeutics Company Profile
Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.
Featured Stories
- Five stocks we like better than Viking Therapeutics
- What is a SEC Filing?
- MarketBeat Week in Review – 4/29 – 5/3
- What is the Hang Seng index?
- Apple’s Earnings Show Investors Its Strength and Its Weakness
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- Bargain Alert: 3 Large Caps With Extremely Oversold RSIs
Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.